title: Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase.
authors.affiliation: The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Carlos E
authors.initials: CE
authors.lastname: Vigil
authors.forename: Sa A
authors.initials: SA
authors.lastname: Wang
authors.forename: Jorge E
authors.initials: JE
authors.lastname: Cortes
authors.forename: Carlos
authors.initials: C
authors.lastname: Bueso-Ramos
authors.forename: Srdan
authors.initials: S
authors.lastname: Verstovsek
authors.forename: Roman
authors.initials: R
authors.lastname: Shinder
authors.forename: Su S
authors.initials: SS
authors.lastname: Chen
authors.forename: Ruth L
authors.initials: RL
authors.lastname: Katz
authors.forename: Abha
authors.initials: A
authors.lastname: Khanna
authors.forename: Bita
authors.initials: B
authors.lastname: Esmaeli
authors.forename: John T
authors.initials: JT
authors.lastname: Manning
authors.forename: M James
authors.initials: MJ
authors.lastname: You
authors.forename: Roberto N
authors.initials: RN
authors.lastname: Miranda
mesh_terms: D001752:Blast Crisis / Q000175:diagnosis / Q000473:pathology*; D001853:Bone Marrow / Q000473:pathology; D000069439:Dasatinib; D005269:Femur / Q000473:pathology; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D034721:Mastocytosis, Systemic / Q000188:drug therapy / Q000473:pathology*; D008875:Middle Aged; D009918:Orbital Neoplasms / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D019009:Proto-Oncogene Proteins c-kit / Q000032:analysis; D011743:Pyrimidines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D019009:Proto-Oncogene Proteins c-kit; D000069439:Dasatinib